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Diagnostic yield of flexible bronchoscopy without fluoroscopic 
guidance in evaluating lung masses
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Background: Bronchoscopy has been widely used in the evaluation of 
lung masses, but little is known about the diagnostic yield of ﬂexible 
bronchoscopy without ﬂuoroscopic guidance in the evaluation of lung 
masses without endobronchial abnormality. 
Methods: We retrospectively reviewed the medical records of all pa-
tients who underwent bronchoscopy at St. Paul’s Hospital, the Catholic 
University of Korea from March 1999 to May 2004. One hundred ﬁfty-
one patients had lung masses without endobronchial lesions. Among 
them 47 patients were excluded because of ﬁlm loss or inadequate 
medical records and an additional 11 patients were excluded because 
the masses were concluded as inactive lesions by clinical follow-up.
Results: Of 93 patients, 38 patients had malignant lesions, 46 had 
benign diseases, and a deﬁnite diagnosis was not obtained in the 
remaining 9. The overall diagnostic rate was 65% (60 of 93) and the 
diagnostic sensitivity of bronchoscopy in malignant and benign lesions 
were 68% (26 of 38) and 74% (34 of 46), respectively. The diagnostic 
yield of transbronchial lung biopsy (46%, 36 of 79) was higher than 
that of bronchial washing (28%, 26 of 93) or brushing (29%, 26 of 
91) (p=0.031). Malignant lesions showed a higher diagnostic yield by 
transbronchial lung biopsy (70%, 22 of 31) compared to benign lesions 
(35%, 14 of 40) (p=0.009). The sensitivity for lesions 2 cm or less in 
size was lower (11%) than that for lesions greater than 2 cm (70.2%) 
(p=0.001). When we grouped the lesions according to the distance 
from the hilum, the diagnostic sensitivity of bronchoscopy for lesions 
in inner third, middle third, and outer third were 72% (36 of 46), 48% 
(12 of 25), and 68% (14 of 22), respectively. There was no difference 
in diagnostic yield depending on the anatomical location of the lesions 
(upper lobe, 65%; middle lobe, 64%; lower lobe, 65%). Pneumothora-
ces and signiﬁcant bleeding developed in 4.3% (4 of 93) and 2.2% (2 
of 93), respectively. None of the patients required closed tube drainage 
nor intubation.
Conclusions: According to the results of our study, the diagnostic yield 
of ﬂexible bronchoscopy without the assist of ﬂuoroscopic guidance 
is comparable to that using ﬂuoroscopy reported previously. Size is 
an important determinant in terms of diagnostic yield. For lesions 
greater than 2 cm, sampling procedures using bronchoscopy should be 
performed whereas for lesions 2 cm or less, other diagnostic procedures 
should be considered. 
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A phase 2 study of picoplatin monotherapy for patients with small 
cell lung cancer (SCLC) who have resistant or refractory disease or 
have relapsed within 180 days of completing first-line, platinum-
containing chemotherapy
Karlin, David A.1 Breitz, Hazel2 Baker, Gizelle2 The Picoplatin Sclc 
Study Group3 
1 Poniard Pharmaceuticals, Inc., South San Francisco, CA, USA 2 
Poniard Pharmaceuticals, Inc., Seattle, WA, USA 3 Multiple Institutions, 
Russia and America 
Background: Picoplatin is a sterically hindered platinum analogue that 
was rationally designed to prevent and overcome platinum resistance 
and to have improved safety compared to other platinums. Picoplatin 
monotherapy, studied in >600 patients had broad activity in lung, pros-
tate, ovarian, and other cancers and rare clinically signiﬁcant nephro-
toxicity, ototoxicity, or neurotoxicity (~2% grade 3 and 0% grade 4). 
A small phase 2 study of 2nd line picoplatin monotherapy for SCLC 
had a median survival of 27.0 weeks (95% CI = 16-35) and 4 of 48 
patients (8%) had a partial response and 21 (44%) stable disease; 2 of 
13 (15%) of the platinum-resistant patients had a partial response. This 
present phase 2, multi-center 2nd line picoplatin monotherapy trial was 
conducted to conﬁrm the results of the ﬁrst study. 
Methods: SCLC patients with: ECOG PS 0-2; measurable disease; and 
refractory (failed or progressed through 1st line platinum-containing 
chemotherapy), resistant (initially responded to 1st line platinum-con-
taining chemotherapy and then relapsed/progressed within 90 days), 
or sensitive disease (initially responded and then relapsed/progressed 
between 91 to 180 days) were treated with picoplatin 150 mg/m2 iv 
over 1-2 hours, every 21 days. Tumor response was assessed every 6 
weeks using RECIST criteria. Adverse events (AEs) were graded using 
the NCI CTCAE. 
Results: 77 patients (45 refractory, 26 resistant, 6 sensitive) were 
treated with picoplatin (median number of cycles 2; mean 3.0). The 
most frequently reported AEs of any severity were cough (78%), dys-
pnea (68%), thrombocytopenia (51%), anemia (51%), fatigue (46%), 
neutropenia (37%), nausea (37%), and emesis (17%). The frequency 
of grade 3-4 hematologic toxicity was: anemia (17.5%), thrombocyto-
penia (36.5%), and neutropenia (17.5%). Neutropenic fever occurred 
in 1 patient. There was no grade 3 or 4 neurotoxicity, ototoxicity, or 
nephrotoxicity. There were no treatment related deaths. Median overall 
survival is 28.1 weeks (44 of 77 death events; 95% CI = 21.4-38.4). 
Median progression free survival is 9.1 weeks (56 of 77 progression 
events; 95% CI = 7.0-12.6). Of 64 patients with at least 1 post-treat-
ment assessment of disease status, 2 (3%) had a partial response and 33 
(52%) had stable disease. 
Conclusion: Picoplatin monotherapy for this predominately refractory 
or resistant population results in median survival and a toxicity proﬁle 
that compares favorably with other therapeutic options for SCLC re-
ported in the literature. A multi-national Phase 3 SPEAR (Study of Pico-
platin Efﬁcacy After Relapse) study is underway to demonstrate median 
survival superiority of picoplatin monotherapy with best supportive care 
